ArticleInternational journal of medical sciences2026
Haloperidol Triggers RAW264.7 Macrophages Injury through Oxidative Stress-Driven Mitochondrial Dysfunction, Genomic Instability, and Apoptotic Cell Death.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Haloperidol is a widely used first-generation antipsychotic for the management of schizophrenia and acute neurocognitive disorders. However, its potential immunotoxic effects remain poorly understood. This study aimed to investigate the cytotoxic and genotoxic mechanisms of haloperidol in RAW264.7 macrophages, focusing on oxidative stress, mitochondrial dysfunction, and apoptosis. Methods: RAW264.7 macrophages were treated with haloperidol (0-150 μM). Cell viability (MTT), DNA damage (micronucleus and comet assays), ROS production, mitochondrial membrane potential, cytochrome c release, apoptosis (annexin V/PI), death receptor expression and caspase activity were evaluated. N-acetylcysteine (NAC)-based pharmacological rescue was further performed to assess the involvement of ROS in haloperidol-induced cytotoxicity, intracellular ROS generation, and caspase-3 activity. Results: Haloperidol induced significant cytotoxicity, with marked effects observed at concentrations ≥50 μM. DNA damage was evidenced by increased micronucleus formation and elevated comet assay parameters. ROS levels were significantly increased, accompanied by mitochondrial membrane depolarization and cytochrome c release. In addition, apoptotic and necrotic cell populations and sub-G1 accumulation were markedly elevated. Mechanistically, both intrinsic and extrinsic apoptotic pathways were activated, as indicated by increased caspase-9, caspase-8, and caspase-3 activities, along with upregulation of Fas and TNFR. NAC pretreatment attenuated haloperidol-induced ROS accumulation, caspase-3 activation, and loss of cell viability, suggesting that ROS accumulation contributes, at least in part, to haloperidol-induced macrophage injury. Conclusions: The present study demonstrates that haloperidol induces cytotoxicity and DNA damage in macrophages through oxidative stress-mediated mitochondrial dysfunction and activation of caspase-dependent apoptotic pathways under high-exposure in vitro conditions. These findings identify macrophages as a potential target of haloperidol toxicity and highlight the importance of considering immune-related effects in safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.